nach oben

Medical Oncology

Erschienen in:

01.05.2017 | Review Article

Targeting TDO in cancer immunotherapy

verfasst von: Cheng-Peng Yu, Yun-Lei Song, Zheng-Ming Zhu, Bo Huang, Ying-Qun Xiao, Da-Ya Luo

Erschienen in: Medical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Tryptophan-2,3-dioxygenase (TDO) is a homotetrameric heme-containing protein catalyzing the initial step in the kynurenine pathway, which oxidates the 2,3-double bond of the indole ring in l-tryptophan and catalyzes it into kynurenine (KYN). The upregulation of TDO results in a decrease in tryptophan and the accumulation of KYN and its metabolites. These metabolites can affect the proliferation of T cells. Increasing evidence demonstrates that TDO is a promising therapeutic target in the anti-tumor process. Despite its growing popularity, there are only a few reviews focusing on TDO in tumors. Hence, we herein review the biological features and regulatory mechanisms of TDO. Additionally, we focus on the role of TDO in the anti-tumor immune response in different tumors. Finally, we also provide our viewpoint regarding the future developmental directions of TDO in cancer research, especially in relation to the development and application of TDO inhibitors as novel cancer treatments.

Phillips RS. Structure, mechanism, and substrate specificity of kynureninase. J Biochim Biophys Acta. 2011;1814(1814):1481–8. doi:10.1016/j.bbapap.2010.12.003.CrossRef

Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Recent Adv Tryptophan Res. 1996;. doi:10.1007/978-1-4613-0381-7_45.

Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. J Immunology. 2002;107(4):452–60. doi:10.1046/j.1365-2567.2002.01526.x.CrossRef

Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101(2):151–5. doi:10.1002/ijc.10645.PubMedCrossRef

Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–8. doi:10.4049/jimmunol.0903670.PubMedPubMedCentralCrossRef

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. J Nat. 2011;478(7368):197–203. doi:10.1038/nature10491.CrossRef

Kotake Y, Masayama IZ. Uber den Mechanismus der kynureninbildung aus tryptophan. J Z Physiol Chem. 1936;243:237–44.CrossRef

Hu X, Bao Z, Hu J, Shao M, Zhang L, Bi K, Zhan A, Huang X. Cloning and characterization of tryptophan-2,3-dioxygenase gene of Zhikong scallop Chlamys farreri (Jones and Preston 1904). J Aquac Res. 2006;37:1187–94.CrossRef

Mukabayire O, Cornel AJ, Dotson EM, Collins FH, Besansky NJ. The tryptophan oxygenase gene of Anopheles gambiae. J Insect Biochem Mol Biol. 1996;26:525–8. doi:10.1016/S0965-1748(96)00026-4.CrossRef

10.

Lorenzen MD, Brown SJ, Denell RE, Beeman RW. Cloning and characterization of the Tribolium castaneum eye-color genes encoding tryptophan oxygenase and kynurenine 3-monoxygenase. J Genet. 2002;160:225–34.

11.

Fabrick JA, Kanost MR, Baker JE. RNAi-induced silencing of embryonic tryptophan oxygenase in the Pyralid moth, Plodia interpunctella. J Insect Sci. 2004;4(1):103–8. doi:10.1673/031.004.1501.CrossRef

12.

Searles LL, Voelker RA. Molecular characterization of the drosophila vermilion locus and its suppressible alleles. J Proc Natl Acad Sci USA. 1986;83:404–8.CrossRef

13.

Tshimura Y, Nozaki M, Hayaishi O. The oxygenated form of l-tryptophan 2,3-dioxygenase as reaction intermediate. J Biol Chem. 1970;245(14):3593–602.

14.

Iwamoto Y, Lee IS, Tsubaki M, Kido R. Tryptophan-2, 3-dioxygenase in Saccharomyces cerevisiae. Can J Microbiol. 1995;141:19–26.CrossRef

15.

Matsumura M, Osada K, Aiba S. L-tryptophan-2, 3-dioxygenase of a moderate thermophile, Bacillus brevis, purification, properties and a substrate-mediated stabilization of the quaternary structure. Biochim Biophys Acta. 1984;786:9–17.PubMedCrossRef

16.

Ball HJ, Jusof FF, Bakmiwewa SM, Hunt NH, Yuasa HJ. Tryptophan-catabolizing enzymes-party of three. J Front Immunol. 2014;5(485):1–10. doi:10.3389/fimmu.2014.00485.

17.

Comings DE, Muhleman D, Dietz G, Sherman M, Forest GL. Sequence of human tryptophan 2, 3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat. J Genomics. 1995;29(2):390–6. doi:10.1006/geno.1995.9990.CrossRef

18.

Gongkai JIAO, Xiao-yan KE, Lu CHENG, Ying ZHOU, Ping CHEN, Bei-li SUN, et al. Positive association between tryptophan-2, 3-dioxygenase gene polymorphism and autistic disorder in Chinese Han population. Chin Med J. 2010;123(2):82.

19.

Comings DE, Gade R, Muhleman D, Chiu C, Wu S, To M, et al. Exon and intron variants in the human tryptophan 2, 3 dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders. J Pharmacogenet Genomics. 1996;6(4):307–18. doi:10.1097/00008571-199608000-00004.CrossRef

20.

Britan A, Maffre V, Tone S, Vet JR. Quantitative and spatial differences in the expression of tryptophan metabolizing enzymes in mouse epididymis. J Cell Tissue Res. 2006;324(2):301–10. doi:10.1007/s00441-005-0151-7.CrossRef

21.

Minatogawa Y, Suzuki S, Ando Y, Tone S, Takikawa O. Tryptophan pyrrole ring cleavage enzymes in placenta. J Adv Exp Med Biol. 2003;527:425–34. doi:10.1007/978-1-4615-0135-0_50.CrossRef

22.

Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D. Identification of tryptophan-2, 3-dioxygenase RNA in rodent brain. J Neurochem. 1993;60:1159–62.PubMedCrossRef

23.

Doherty LF, Kwon HE, Taylor HS. Regulation of tryptophan 2,3-dioxygenase by HOXA10 enhances embryo viability through serotonin signaling.J. Am J Physiol Endocrinol Metab. 2011;300(1):86–93. doi:10.1152/ajpendo.00439.2010.CrossRef

24.

Wu W, Nicolazzo JA, Wen L, Chung R, Stankovic R, Bao SS, et al. Expression of tryptophan-2, 3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer’s disease brain. PLoS One. 2013;8:e59749.PubMedPubMedCentralCrossRef

25.

Miller C, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. J Neurobiol Dis. 2004;15(3):618–29. doi:10.1016/j.nbd.2003.12.015.CrossRef

26.

Yu CP, Pan ZZ, Luo DY. TDO as a therapeutic target in brain diseases J. Metab Brain Dis. 2016;31(4):737–47. doi:10.1007/s11011-016-9824-z.PubMedCrossRef

27.

Mørland J, Stowell L, Gjerde H. Ethanol increases rat liver tryptophan oxygenase: evidence for corticosterone mediation. Alcohol. 1985;2:255–9. doi:10.1016/0741-8329(85)90055-2.PubMedCrossRef

28.

Badawy AA. Tryptophan metabolism in alcoholism. Nutr Res Rev. 2002;15:123–52. doi:10.1079/NRR200133.PubMedCrossRef

29.

Mehler AH, Knox WE. The conversion of tryptophan to Kynurenine in liver II. The enzymatic hydrolysis of formylkynurenine. J Biol Chem. 1950;187(1):431–8.PubMed

30.

Knox WE, Mehler AH. The adaptive increase of the tryptophan peroxidase-oxidase system of liver. J Sci. 1951;113(2931):237–8.CrossRef

31.

Danesch U, Gloss B, Schmid W, Schütz G, Schüle R, Renkawitz R. Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoid-responsive elements. Embo J. 1987;6(3):625–30.PubMedPubMedCentral

32.

Ren S, Correia MA. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase? J Arch Biochem Biophys. 2000;377(1):195–203. doi:10.1006/abbi.2000.1755.CrossRef

33.

Nakamura T, Shinno HI, Chihara A. Insulin and glucagon as a new regulator system for tryptophan oxygenase activity demonstrated in primary cultured rat hepatocytes. J Biol Chem. 1980;255:7533–5.PubMed

34.

Braidman IP, Rose DP. Effects of sex hormones on three glucocorticoid inducible enzymes concerned with amino acid metabolism in rat liver. J Endocrinol. 1971;89:1250–5.CrossRef

35.

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. J Proc Natl Acad Sci USA. 1971;109(7):2497–502.CrossRef

36.

D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, et al. TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. J Cancer Res. 2015;75(21):4651–64. doi:10.1158/0008-5472.CAN-15-2011.CrossRef

37.

Hsu Ya-Ling, Hung Jen-Yu, Chiang Shin-Yi, Jian Shu-Fang, Cheng-Ying Wu, Lin Yi-Shiuan, et al. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. J Oncotarget. 2014;7(19):27584–98. doi:10.18632/oncotarget.8488.

38.

Chen IC, Lee KH, Hsu YH, et al. Expression pattern and clinicopathological relevance of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase protein in colorectal cancer. J Dis Markers. 2016;2016(3):1–9. doi:10.1155/2016/8169724.

39.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C. Tryptophan catabolism generates autoimmune- preventive regulatory T cells. Transp Immunol. 2006;17(1):58–60. doi:10.1016/j.trim.2006.09.017.CrossRef

40.

Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–42. doi:10.1016/j.immuni.2005.03.013.PubMedCrossRef

41.

Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. J. Nat Rev Immunol. 2007;7(10):817–23. doi:10.1038/nri2163.CrossRef

42.

Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Taylor PA, Mellor AL, Munn DH, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2008;111(6):3257–65. doi:10.1182/blood-2007-06-096081.PubMedPubMedCentralCrossRef

43.

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197–203. doi:10.1038/nature10491.PubMedCrossRef

44.

Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787. doi:10.1182/blood-2007-06-09608.PubMedPubMedCentralCrossRef

45.

Hayashi T, Raz E. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci. 2007;104(47):18619–24. doi:10.1073/pnas.0709261104.PubMedPubMedCentralCrossRef

46.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752–61. doi:10.4049/jimmunol.176.11.6752.PubMedCrossRef

47.

Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069–77. doi:10.1038/sj.cdd.4401073.PubMedCrossRef

48.

Weber WP, Feder-Mengus C, Chiarugi A, Rosenthal R, Reschner A, Schumacher R, et al. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8⁺ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2006;36(2):296–304. doi:10.1002/eji.200535616.PubMedCrossRef

49.

Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. J Sci Transl Med. 2010;2(32):32ra36. doi:10.1126/scitranslmed.3000632.

50.

Zaher SS, Germain C, Fu H, Larkin DF, George AJ. 3-hydroxykynurenine suppresses CD4⁺ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci. 2011;52(5):2640–8. doi:10.1167/iovs.10-5793.PubMedPubMedCentralCrossRef

51.

Mi YK, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD⁺ into a nuclear signal. Genes Dev. 2005;19(17):1951. doi:10.1101/gad.1331805.CrossRef

52.

Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, Ahrendt T, et al. The endogenous tryptophan metabolite and NAD⁺ precursor quinolinic acid confers resistance of gliomas to oxidative stress. J Cancer Res. 2013;73(11):3225–34. doi:10.1158/0008-5472.CrossRef

53.

Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, et al. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005;25(6):981–93. doi:10.1007/s10571-005-8469-y.PubMedCrossRef

54.

Bresjanac M, Antauer G. Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRalpha1 as well as GDNF in vivo. J Exp Neurol. 2000;164(1):53–9. doi:10.1006/exnr.2000.7416.CrossRef

55.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11(3):312–9. doi:10.1038/nm1196.PubMedCrossRef

56.

Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147–54. doi:10.1172/JCI31178.PubMedPubMedCentralCrossRef

57.

Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–74. doi:10.1038/nm934.PubMedCrossRef

58.

Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396(1):203–13.PubMedCrossRef

59.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(67):7082–7. doi:10.1158/0008-5472.PubMedCrossRef

60.

Löb S, Königsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: Can we see the wood for the trees? Nat Rev Cancer. 2009;9(6):445. doi:10.1038/nrc2639.PubMedCrossRef

61.

Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, et al. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother. 2013;62(5):829–37. doi:10.1007/s00262-013-1393-y.PubMedPubMedCentralCrossRef

62.

Astigiano S, Morandi B, Costa R, Mastracci L, D’Agostino A, Ratto GB, Melioli G, Frumento G. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. J Neoplasia. 2005;7(4):390–6. doi:10.1593/neo.04658.CrossRef

63.

Schmidt SK, Siepmann S, Kuhlmann K, Meyer HE, Metzger S, Pudelko S, et al. Influence of tryptophan contained in 1-methyl-tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase. Plos One. 2012;7(7):e44797. doi:10.1371/journal.Pone.0044797.PubMedPubMedCentralCrossRef

64.

Wenzel H. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289(1–2):42–8. doi:10.1016/j.Cellimm.2014.02.005.

65.

Frumento Guido, Rotondo Rita, Tonetti Michela, Damonte Gianluca, Benatti Umberto, Ferrara Giovanni Battista. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196(4):459–68. doi:10.1084/jem.20020121.PubMedPubMedCentralCrossRef

66.

Song H, Park H, Kim YS, Kim KD, Lee HK, Cho DH, et al. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol. 2011;11(8):932–8. doi:10.1016/j.intimp.2011.02.005.PubMedCrossRef

67.

Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2015;99:180–5. doi:10.1016/j.addr.2015.11.009.PubMedCrossRef

68.

Gonzalezgugel E, Saxena M, Bhardwaj N. Modulation of innate immunity in the tumor microenvironment.J. Cancer Immunol Immunother. 2016;65(10):1–8. doi:10.1007/s00262-016-1859-9.

69.

Burga Rachel A, Nguyen Tuongvan, Zulovich Jane, Madonna Sarah, Ylisastigui Loyda, Fernandes Rohan. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells J. Cytotherapy. 2016;18(11):1410–21. doi:10.1016/j.jcyt.2016.05.018.PubMedCrossRef

70.

Shissler SC, Bollino DR, Tiper IV, Bates JP, Derakhshandeh R, Webb TJ. Immunotherapeutic strategies targeting natural killer T cell responses in cancer J. Immunogenetics. 2016;8:1–16. doi:10.1007/s00251-016-0928-8.

71.

Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. J Biochem Pharmacol. 1995;49(10):1435–42. doi:10.1016/0006-2952(95)00006-L.CrossRef

72.

Gibney SM, Fagan EM, Waldron AM, O’Byrne J, Connor TJ, Harkin A. Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int J Neuropsychopharmacol. 2014;17(6):917–28. doi:10.1017/S1461145713001673.PubMedCrossRef

73.

Wu JS, Lin SY, Liao FY, Hsiao WC, Lee LC, Peng YH, et al. Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening. J Med Chem. 2015;58(19):7807–19. doi:10.1021/acs.jmedchem.5b00921.PubMedCrossRef

74.

Abdelmagid AF. Targeting the inhibition of tryptophan 2,3-dioxygenase (TDO-2) for cancer treatment. ACS Med Chem Lett. 2017;8:11–3. doi:10.1021/acsmedchemlett.6b00458.CrossRef

Titel: Targeting TDO in cancer immunotherapy
verfasst von: Cheng-Peng Yu
Yun-Lei Song
Zheng-Ming Zhu
Bo Huang
Ying-Qun Xiao
Da-Ya Luo
Publikationsdatum: 01.05.2017
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-0933-2

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Targeting TDO in cancer immunotherapy

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies

Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy

Systematic review: isocaloric ketogenic dietary regimes for cancer patients

ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features

LincRNa-p21: function and mechanism in cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie